NASDAQ:CALT - Calliditas Therapeutics AB (publ) Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 21.68 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$31.23
▼ -0.89 (-2.77%)
1 month | 3 months | 12 months
Get New Calliditas Therapeutics AB (publ) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$38.00
▲ +21.68% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Calliditas Therapeutics AB (publ) in the last 3 months. The average price target is $38.00, with a high forecast of $44.00 and a low forecast of $28.00. The average price target represents a 21.68% upside from the last price of $31.23.
Buy
The current consensus among 4 investment analysts is to buy stock in Calliditas Therapeutics AB (publ).

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/28/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/18/2020Ci CapitalReiterated RatingBuy$44.00Low
i
7/1/2020CitigroupInitiated CoverageBuy$36.00High
i
6/30/2020Jefferies Financial GroupInitiated CoverageBuy$44.00High
i
6/30/2020Stifel NicolausInitiated CoverageBuy$28.00High
i
(Data available from 1/27/2016 forward)
Calliditas Therapeutics AB (publ) logo
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Read More

Today's Range

Now: $31.23
$31.23
$31.42

50 Day Range

MA: $32.68
$30.00
$34.74

52 Week Range

Now: $31.23
$19.00
$38.00

Volume

1,955 shs

Average Volume

15,428 shs

Market Capitalization

$748.55 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Calliditas Therapeutics AB (publ)?

The following equities research analysts have issued reports on Calliditas Therapeutics AB (publ) in the last twelve months: Ci Capital, Citigroup Inc., Jefferies Financial Group Inc., Stifel Nicolaus, and Zacks Investment Research.

What is the current price target for Calliditas Therapeutics AB (publ)?

4 Wall Street analysts have set twelve-month price targets for Calliditas Therapeutics AB (publ) in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 21.7%. Jefferies Financial Group Inc. has the highest price target set, predicting CALT will reach $44.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $28.00 for Calliditas Therapeutics AB (publ) in the next year.

What is the current consensus analyst rating for Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CALT will outperform the market and that investors should add to their positions of Calliditas Therapeutics AB (publ).

What other companies compete with Calliditas Therapeutics AB (publ)?

How do I contact Calliditas Therapeutics AB (publ)'s investor relations team?

Calliditas Therapeutics AB (publ)'s physical mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company's listed phone number is 46-8411-3005 and its investor relations email address is [email protected] The official website for Calliditas Therapeutics AB (publ) is www.calliditas.se.